Background: This study evaluated the efficacy of L-carnitine in managing hyperlipidemia, a key risk factor for cardiovascular diseases. In a 12-week, double-blind, randomized controlled trial, 100 participants with hyperlipidemia were randomized; where one group were received L-carnitine (1 g/day) as an aduvant therapy combined with a hypolipidemic drug and the other group with hypolipidemic drug alone. The primary outcomes measured were changes in serum levels of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, while secondary outcomes included body weight and BMI. The L-carnitine group showed a significant reduction in total cholesterol (20.4 ± 11.1 mg/dL), LDL cholesterol (14.6 ± 9.6 mg/dL), and triglycerides (25.6 ± 14.5 mg/dL), with an increase in HDL cholesterol (6.6 ± 4.6 mg/dL), all statistically significant (p<0.05) compared to the other group. No significant changes were observed in body weight or BMI. The results suggest that L-carnitine supplementation could be an effective adjunct therapy for improving lipid profiles in hyperlipidemia patients, though further long-term studies are needed.